Issue 115  • February 2022

Anaesthesia drugs worst-hit by US drug shortages

A cloudy day in paradise for pharma tax havens  

Aduhelm qualms continue with Medicare verdict

In association with

Mapping the RNA therapeutics R&D landscape in 2022 

Fueled by the successful utilisation of the mRNA Covid-19 vaccines, RNA therapeutics are expected to make larger strides in 2022

In association with

02/24/2024 14:17:37
  • Home | Mapping the RNA therapeutics R&D landscape in 2022 
  • In this issue
  • Contents
  • CSafe Global
  • Briefing
  • Industry news
  • The pharma industry briefing
  • Covid-19 executive briefing by GlobalData
  • HOF Sonderanlagenbau
  • BEA Technologies
  • Comment
  • Restrictive Medicare coverage spells continued uncertainty for Aduhelm
  • 2021: a record year for orphan therapies
  • Trikafta/Kaftrio continues to be a game-changer for cystic fibrosis patients
  • Mimotopes Company Insight
  • Mimotopes
  • In Depth
  • Mapping the RNA therapeutics R&D landscape in 2022
  • A cloudy day in paradise for pharma tax havens in Cayman Islands & Bermuda?
  • Pharmaceutical Technology Excellence Awards 2021 – Winners Announced!
  • How technology could transform drug research in 2022
  • Anaesthesia drugs worst-hit by US drug shortages
  • Molnar-Institute Company Insight
  • Molnar-Institute
  • In Data
  • Asia-Pacific sees the largest growth in metabolic disorders-related trials over
  • The Middle East has seen the largest growth in infectious disease-related trials over the past decade
  • Global markets and indices
  • Macro-economic indicators
  • Macro-economic indicators (page 2)
  • Baxter
  • Events
  • Next issue
01/20/2022 00:00:00